Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 25:12:855725.
doi: 10.3389/fonc.2022.855725. eCollection 2022.

Advances in Hodgkin Lymphoma: Including the Patient's Voice

Christine Moore Smith  1   2 , Debra L Friedman  1   2
Affiliations

Advances in Hodgkin Lymphoma: Including the Patient's Voice

Christine Moore Smith et al. Front Oncol. .

Abstract

Since the initial treatment with radiation therapy in the 1950s, the treatment of Hodgkin lymphoma has continued to evolve, balancing cure and toxicity. This approach has resulted in low rates of relapse and death and fewer short and late toxicities from the treatments used in pursuit of cure. To achieve this balance, the field has continued to progress into an exciting era where the advent of more targeted therapies such as brentuximab vedotin, immunotherapies such as PD-1 inhibitors, and chimeric antigen receptor T-cells (CAR-T) targeted at CD30 are changing the landscape. As in the past, cooperative group and international collaborations are key to continuing to drive the science forward. Increased focus on patient-reported outcomes can further contribute to the goal of improved outcomes by examining the impact on the individual patient in the acute phase of therapy and on long-term implications for survivors. The goals of this review are to summarize recent and current clinical trials including reduction or elimination of radiation, immunotherapies and biologically-targeted agents, and discuss the use of patient-reported outcomes to help discern directions for new therapeutic regimens and more individualized evaluation of the balance of cure and toxicity.

Keywords: Hodgkin; Hodgkin lymphoma (HL); immunotherapy; lymphoma; patient-reported outcomes; survivorship; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. American Cancer Society . Cancer Facts & Figures 2020. Atlanta: American Cancer Society; (2020). Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/caff200.... - PMC - PubMed
    1. Flerlage JE, Metzger ML, Bhakta N. The Management of Hodgkin Lymphoma in Adolescents and Young Adults: Burden of Disease or Burden of Choice? Blood (2018) 132(4):376–84. doi: 10.1182/blood-2018-01-778548 - DOI - PMC - PubMed
    1. Kahn JM, Kelly KM. Adolescent and Young Adult Hodgkin Lymphoma: Raising the Bar Through Collaborative Science and Multidisciplinary Care. Pediatr Blood Cancer (2018) 65(7):1–19. doi: 10.1002/pbc.27033 - DOI - PMC - PubMed
    1. Ries L, Smith M, Gurney J, Linet M, Tamra T, Young JL, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 (1999). Bethesda, MD: National Cancer Institute, SEER Program. NIH Pub. No. 9904649. Available at: https://seer.cancer.gov/archive/publications/childhood/ (Accessed January 5, 2022).
    1. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. Seer Cancer Statistics Review, 1975-2018. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2018/ (Accessed January 5, 2022).